Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. The pathological features of AD comprise a complex set of histopathological changes within the brain. Symptoms typically begin to first appear in patients in their mid-sixties, and appear in varying stages. The effects of AD, particularly at an advanced stage, are devastating to patients and their caregivers, and are associated with significant associated healthcare costs.
Current treatments focus on sustaining the patient’s cognitive function, managing behavioural symptoms and slowing down the rate of disease progression. There is currently no cure for AD, and only six symptomatic treatment therapies have been approved, of which one (Cognex) is no longer available in the US. The current market leaders are suboptimal in terms of efficacy, and there is therefore a large unmet need within AD to develop safer and more efficacious treatments.
There are numerous differences between many of these products due to their mechanisms of action, and these must be understood fully by companies seeking to position a novel drug in this market. This tabular heatmap framework, designed to provide an easily digestible Summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the AD market and Phase III pipeline. These are split along therapy lines, and are therefore reflective of the treatment algorithm.
All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.
The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.
- What preventative early-stage drugs are generating interest within the AD pipeline? - Will the current AD market landscape ensure that the first drug with a disease-modifying mechanism of action will become the market leader? - What are the clinical characteristics of currently approved therapies for AD, in terms of specific safety and efficacy parameters? - What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them? - How will current late-stage molecules affect the market for AChEIs, and are they able to yield comparable clinical efficacy results? - With three amyloid inhibitors present in the late-stage pipeline, do they have sufficient differentiating characteristics from previous clinical failures from this class to have an impact on the market?
Reasons to buy
- Understand the current clinical landscape by considering the treatment options available by drug class. - Visually compare the currently approved treatments available by drug class, based on the most important efficacy and safety parameters tested in clinical trials. - Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy - Understand the relative strengths and weaknesses of the studies used to gather these data. - Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks. - Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.
Our reports have been used by over 10K customers, including:
Chorea Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Chorea Global Clinical Trials Review, H2, 2018" provides an overview of Chorea clinical trials scenario.This report provides top line data relating to the clinical trials on Chorea. Report includes...
Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Pipeline Review, H2 2018 Summary Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) pipeline Target constitutes close to 6 molecules. Out of which approximately 2 molecules are developed by companies and remaining by the...
172 pages •
By Transparency Market Research
• Dec 2018
Dementia Treatment Market - Overview This report analyzes the current and future scenario of the global dementia associated with Alzheimer’s disease market for the period 2018 to 2026. Rise in geriatric population, increased prevalence of Alzheimer’s, high unmet medical needs, and rich pipeline are likely to be major...
15 Companies Make Active Investments in Mild Cognitive Impairment (MCI) Pipeline Drugs The global demand for Mild Cognitive Impairment (MCI) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Mild Cognitive Impairment (MCI) pipeline. Companies...
Batten Disease Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Batten Disease Global Clinical Trials Review, H2, 2018" provides an overview of Batten Disease clinical trials scenario.This report provides top line data relating to the clinical trials on Batten...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.